Diabeloop announced that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system.
Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia.
According to a news release, the 974-patient cohort demonstrated an increase of 18.4% in time in range, an improvement associated with better glucose control, fewer complications and improved quality of life in patients with type 1 diabetes. The company said the performance confirms Diabeloop’s platform’s ability to improve glycemic control in the real-life environment, which is less controlled than in hospital-supervised studies.
RELATED: CathVision concludes patient enrolment in EP recording technology trial
DBLG1 also demonstrated a significant reduction in time spent in hypoglycemia, with users whose HbA1c was available at initiation spending just 0.9% of the time below 70 mg/dL and 0.1% of the time below 54 mg/dL5.
The company said the hypoglycemia data shows that DBLg1 contributes to the reduction in risks such as discomfort, dizziness and even life-threatening situations.
“It is a great satisfaction to see that these new data extracted from an even larger cohort of patients show a simultaneous performance on TIR and reduction of hypoglycemia,” Diabeloop CEO and co-founder Erik Huneker said in the release. “Combined with the positive and very concrete feedback from the people equipped, this motivates us to go even further, to address more and more populations affected by diabetes.”
